Integrative Physiology |
From the Departments of Bioengineering (M.R., A.J.R.), Radiology (Y.C., P.B.C.), and Physiology and Biophysics (P.B.C.), School of Medicine, University of Washington, Seattle, Wash.
Correspondence to Michael Regnier, Department of Bioengineering, Box 357962, School of Medicine, University of Washington, Seattle, WA 98195-7962. E-mail mregnier{at}u.washington.edu
AbstractTo investigate the kinetic parameters of the crossbridge cycle that regulate force and shortening in cardiac muscle, we compared the mechanical properties of cardiac trabeculae with either ATP or 2-deoxy-ATP (dATP) as the substrate for contraction. Comparisons were made in trabeculae from untreated rats (predominantly V1 myosin) and those treated with propylthiouracil (PTU; V3 myosin). Steady-state hydrolytic activity of cardiac heavy meromyosin (HMM) showed that PTU treatment resulted in >40% reduction of ATPase activity. dATPase activity was >50% elevated above ATPase activity in HMM from both untreated and PTU-treated rats. Vmax of actin-activated hydrolytic activity was also >50% greater with dATP, whereas the Km for dATP was similar to that for ATP. This indicates that dATP increased the rate of crossbridge cycling in cardiac muscle. Increases in hydrolytic activity were paralleled by increases of 30% to 80% in isometric force (Fmax), rate of tension redevelopment (ktr), and unloaded shortening velocity (Vu) in trabeculae from both untreated and PTU-treated rats (at maximal Ca2+ activation), and F-actin sliding speed in an in vitro motility assay (Vf). These results contrast with the effect of dATP in rabbit psoas and soleus fibers, where Fmax is unchanged even though ktr, Vu, and Vf are increased. The substantial enhancement of mechanical performance with dATP in cardiac muscle suggests that it may be a better substrate for contractility than ATP and warrants exploration of ribonucleotide reductase as a target for therapy in heart failure.
Key Words: in vitro motility hypothyroid myosin isoforms contractile kinetics shortening velocity
This article has been cited by other articles:
![]() |
T. E. Gillis, D. A. Martyn, A. J. Rivera, and M. Regnier Investigation of thin filament near-neighbour regulatory unit interactions during force development in skinned cardiac and skeleta muscle J. Physiol., April 15, 2007; 580(2): 561 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Stelzer, S. L. Brickson, M. R. Locher, and R. L. Moss Role of myosin heavy chain composition in the stretch activation response of rat myocardium J. Physiol., February 15, 2007; 579(1): 161 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Schoffstall, N. M. Brunet, S. Williams, V. F. Miller, A. T. Barnes, F. Wang, L. A. Compton, L. A. McFadden, D. W. Taylor, M. Seavy, et al. Ca2+ sensitivity of regulated cardiac thin filament sliding does not depend on myosin isoform J. Physiol., December 15, 2006; 577(3): 935 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Razumova, J. F. Shaffer, A.-Y. Tu, G. V. Flint, M. Regnier, and S. P. Harris Effects of the N-terminal Domains of Myosin Binding Protein-C in an in Vitro Motility Assay: EVIDENCE FOR LONG-LIVED CROSS-BRIDGES J. Biol. Chem., November 24, 2006; 281(47): 35846 - 35854. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Burnstock Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev., March 1, 2006; 58(1): 58 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Clemmens, M. Entezari, D. A Martyn, and M. Regnier Different effects of cardiac versus skeletal muscle regulatory proteins on in vitro measures of actin filament speed and force J. Physiol., August 1, 2005; 566(3): 737 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Song, Z. F. Pursell, W. C. Copeland, M. J. Longley, T. A. Kunkel, and C. K. Mathews DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity PNAS, April 5, 2005; 102(14): 4990 - 4995. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Schoffstall, A. Kataoka, A. Clark, and P. B. Chase Effects of Rapamycin on Cardiac and Skeletal Muscle Contraction and Crossbridge Cycling J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 12 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Stelzer, J. R. Patel, M. C. Olsson, D. P. Fitzsimons, L. A. Leinwand, and R. L. Moss Expression of cardiac troponin T with COOH-terminal truncation accelerates cross-bridge interaction kinetics in mouse myocardium Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1756 - H1761. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kohler, Y. Chen, B. Brenner, A. M. Gordon, T. Kraft, D. A. Martyn, M. Regnier, A. J. Rivera, C.-K. Wang, and P. B. Chase Familial hypertrophic cardiomyopathy mutations in troponin I (K183{Delta}, G203S, K206Q) enhance filament sliding Physiol Genomics, July 7, 2003; 14(2): 117 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Sieck and M. Regnier Plasticity in Skeletal, Cardiac, and Smooth Muscle: Invited Review: Plasticity and energetic demands of contraction in skeletal and cardiac muscle J Appl Physiol, March 1, 2001; 90(3): 1158 - 1164. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |